Pamiparib

Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy). It is grouped under the following drug class(es): PARP Inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include 5, 6, 7a, 11-Tetraazacyclohepta(def)cyclopenta(a)fluoren-4(7H)-one, 2-fluoro-5, 8, 9, 10, 10a, 11-hexahydro-10a-methyl-, (10aR)- and pamiparibum. Its PubChem CID is 135565554.

CAS No 1446261-44-4
Molecular Formula C16H15FN4O
Molecular Weight 298.31 g/mol
Synonyms (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one

Frequently Asked Questions